Back to results
US 2010/0136700 A1Published application
Metabolic syndrome and hpa axis biomarkers for major depressive disorder
AssigneeRidge Diagnostics, Inc.
InventorsJohn Bilello, Bo Pi
Life of this patent
Estimating the term…
Abstract
Materials and methods for using combinations of metabolic syndrome and HPA axis biomarkers for monitoring major depressive disorder.
Claims29
A method for determining whether a human subject has depression, comprising
- (a) providing numerical values for a plurality of parameters predetermined to be relevant to depression, wherein the plurality of parameters comprises one or more hypothalamic-pituitary-adrenal (HPA) axis markers and one or more metabolic markers;
- (b) individually weighting each of the numerical values by a predetermined function, each function being specific to each parameter;
- (c) determining the sum of the weighted values;
- (d) determining the difference between the sum and a control value;
- and
- (e) if the difference is greater than a predetermined threshold, classifying the individual as having depression, or, if the difference is not greater than the predetermined threshold, classifying the individual as not having depression.
3 more elements
A method for monitoring treatment of an individual diagnosed with a depression disorder, comprising:
- (a) using an algorithm to determine a first MDD disease score based on the levels of a plurality of analytes in a biological sample from the individual, wherein the plurality of analytes comprise one or more HPA axis biomarkers and one or more metabolic biomarkers;
- (b) using the algorithm to determine a second MDD disease score after treatment of the individual for the depression disorder;
- (c) comparing the score in step (a) to the score in step (b) and to a control MDD disease score, and classifying the treatment as being effective if the score in step (b) is closer than the score in step (a) to the control MDD score, or classifying the treatment as not being effective if the score in step (b) is not closer than the score in step (a) to the control MDD score.
A method for determining whether an individual is likely to have depression, comprising
- (a) providing a biological sample from the individual;
- (b) measuring the level of an analyte in the biological sample, wherein the analyte is selected from the group consisting of apolipoprotein CIII, epidermal growth factor, prolactin, and resistin;
- (c) comparing the measured level with a control level of the analyte;
- and
- (d) if the level of the analyte is greater than the control level, classifying the individual as likely to have depression, or if the level of the analyte is not greater than the control level, classifying the individual as not likely to have depression.
2 more elements
Dependencies are inferred from the claim text.